

ASX: CVB

18 December 2025

Board Update – Non-Executive Director Resignation

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB, “**CurveBeam AI**” or the “**Company**”), a fully integrated developer and manufacturer of point-of-care specialised medical imaging (CT) equipment, supported by a range of AI enabled SaaS-based clinical assessment solutions, advises that Ms Kate Robb has resigned as a Non-Executive Director of the Company, effective today, due to increased professional commitments.

Ms Robb has recently taken on a full-time executive role and is therefore no longer able to commit the time required to continue in her position as a Director of CurveBeam AI.

Ms Robb has served on the Board since April 2023 and has been Chair of the Audit and Risk Committee during that time. The Board sincerely thanks her for a valuable contribution, strong governance leadership and financial expertise, which have been instrumental during a strategically important phase of the Company’s development.

The Chair of the Board, Rob Lilley, said: “On behalf of the Board, I thank Kate for her commitment and the considerable time she has dedicated to the Company over the past three years. Kate was always available to support the Company, and it has been a pleasure to have such a highly professional and experienced director on the Board.”

The Board has commenced a formal process to appoint an Independent Non-Executive Director with the requisite skills and experience to chair the Audit and Risk Committee, and with expertise relevant to the Company’s recently announced joint venture in China. A number of candidates are progressing through the vetting process, with final interviews expected to occur following the holiday period.

In parallel, the Company is also progressing discussions with candidates for an additional Board appointment with US-based, global orthopaedics commercialisation experience, reflecting the Company’s strategic focus on international growth.

The Company will update the market on Board composition and these new appointments as appropriate.

In the interim, the Board will ensure that Audit and Risk Committee responsibilities continue to be appropriately managed.

For further information:

Rob Lilley
Chairman
CurveBeam AI
rob.lilley@curvebeamai.com

Release has been authorised for release by the Chair of the Board.

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au